Marcia Ayer, APRN
Acute Care · Columbus, OHNPI 1952903056
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Jazz Pharmaceuticals Inc. accounts for 64.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $4,589 and has fallen 97.3% since, to $122 in 2025. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $59.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$5K
- Inspire Medical Systems, Inc.$794
- Harmony Biosciences LLC$272
- Axsome Therapeutics, Inc.$267
- Bayer$214
- Avadel CNS Pharmaceuticals, LLC$192
- plus $797 from 11 others
What the payments were for
- Speaking & faculty fees$2,38034%
- Travel & lodging$1,01414%
- Food & beverage$3,32047%
- Education$3485%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 38 | $4,526 |
| Inspire Medical Systems, Inc. | 20 | $794 |
| Harmony Biosciences LLC | 9 | $272 |
| Axsome Therapeutics, Inc. | 10 | $267 |
| Bayer | 5 | $214 |
| Avadel CNS Pharmaceuticals, LLC | 9 | $192 |
| AstraZeneca | 6 | $191 |
| Idorsia Pharmaceuticals US Inc | 8 | $188 |
| Akebia Therapeutics Inc | 2 | $136 |
| Otsuka America Pharmaceutical, Inc. | 3 | $118 |
| Fresenius USA Marketing, Inc. | 2 | $38 |
| Amgen(2 entities) | 2 | $34 |
| Medicomp Inc | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Aurinia Pharma U.S., Inc. | 1 | $17 |
| KCI USA, Inc. | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,062 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 19 | $277,715 |
| SunosiSolriamfetol Hcl | 25 | $24,645 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $23,347 |
| BelsomraSuvorexant | 41 | $22,002 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $13,196 |
| Armodafinil | 136 | $12,061 |
| QuviviqDaridorexant Hcl | 13 | $8,314 |
| Modafinil | 97 | $7,083 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 122 | $6,308 |
| Adderall XrDextroamphetamine/Amphetamine | 12 | $4,345 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 40 | $2,868 |
| Zolpidem Tartrate | 365 | $1,671 |
| Zolpidem Tartrate ErZolpidem Tartrate | 62 | $1,624 |
| Zaleplon | 94 | $1,607 |
| Eszopiclone | 74 | $1,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $272 | $277,71519 claims |
| Axsome Therapeutics, Inc.Sunosi | $267 | $24,64525 claims |
| MerckBelsomra | $14 | $22,00241 claims |
| AstraZenecaBreztri Aerosphere | $191 | $13,19619 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $188 | $8,31413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Columbus
- Ileah ReichertColumbus$73K
- Holly McKibbenColumbus$23K
- Joseph LucasColumbus$5K
- Cody AshColumbus$4K
- Andrea RobinsonCleveland$149K
- Brittney BrowneMonroe$142K
- Jamie McGuireMiamisburg$86K
- Davida PraterBeavercreek$46K
- Dawn FrenchAlliance$40K
- Jody HussBlue Ash$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.